Form 8-K · Current Report · Filed 2024-05-08
Edwards Lifesciences Corporation Announces Voting Results from Annual Meeting
Edwards Lifesciences Corporation reported the voting results from its Annual Meeting of Stockholders held on May 7, 2024.
- Filer
- Edwards Lifesciences Corporation EW · NYSE
- Filed
- Accession
- 0001099800-24-000045
- CIK
- 0001099800
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
All nominated directors were elected, the advisory proposal on executive compensation was approved, the ratification of PricewaterhouseCoopers LLP as the independent auditor was approved, and the amended long-term stock incentive compensation program was approved.
Items reported
Submission of Matters to a Vote of Security Holders
Market reaction
Close before filing
$85.84
Next session
+1.8%
Since filing
+0.3%
Latest close
$86.07
What happened, not what will happen — closing prices around the filing date.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.
Never miss another EW filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.